menu
    • menu

    Company profile for WuXi AppTec

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery an...
    Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient outsourcing solutions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    WuXi AppTecChina Flag
    Country
    Country
    China
    Address
    Address
    WuXi AppTec 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131, Ch...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.wuxiapptec.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Wuxi Apptec Faces New Security Scrutiny From Pentagon: Bloomberg
    Wuxi Apptec Faces New Security Scrutiny From Pentagon: Bloomberg

    04 Dec 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs

    FIERCE PHARMA
    04 Dec 2025
    Share Share
    Frost & Sullivan Names WuXi AppTec as 2025 CRDMO of the Year
    Frost & Sullivan Names WuXi AppTec as 2025 CRDMO of the Year

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wuxi-apptec-receives-frost--sullivans-2025-global-company-of-the-year-award-in-the-crdmo-industry-302620253.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Wuxi Sharpens Focus By Selling Off Clinical Research Units
    Wuxi Sharpens Focus By Selling Off Clinical Research Units

    28 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/cro/wuxi-apptec-sharpens-focus-selling-clinical-research-units

    FIERCE BIOTECH
    28 Oct 2025
    Share Share
    WuXi AppTec Initiates RMB1.03B Interim Dividend Payout
    WuXi AppTec Initiates RMB1.03B Interim Dividend Payout

    21 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wuxi-apptec-implements-its-first-interim-dividend-plan-distributing-rmb1-03-billion-in-cash-dividends-302562337.html

    PR NEWSWIRE
    21 Sep 2025
    Share Share
    WuXi AppTec Wins EcoVadis Gold for Sustainability Again
    WuXi AppTec Wins EcoVadis Gold for Sustainability Again

    08 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wuxi-apptec-awarded-gold-medal-by-ecovadis-sustainability-rating-for-second-consecutive-year-302547481.html

    PR NEWSWIRE
    08 Sep 2025
    Share Share
    WuXi AppTec Completes RMB1B A-Share Buyback, Shares Cancelled
    WuXi AppTec Completes RMB1B A-Share Buyback, Shares Cancelled

    27 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wuxi-apptec-completes-second-rmb1-0-billion-a-share-repurchase-program-in-2025--all-repurchased-shares-to-be-cancelled-302540052.html

    PR NEWSWIRE
    27 Aug 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Exatecan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Exatecan

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37610

    Submission : 2023-06-07

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Mafodotin [Usan]

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Mafodotin [Usan]

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36725

    Submission : 2022-02-03

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Monomethyl Auristatin E

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Monomethyl Auristatin E

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36104

    Submission : 2021-07-22

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    PAYLOAD-LINKER VCMMAE

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PAYLOAD-LINKER VCMMAE

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2021-11-24

    Pay. Date : 2021-04-14

    DMF Number : 34821

    Submission : 2020-05-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    MC-VC-PAB-MMAE

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    MC-VC-PAB-MMAE

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38725

    Submission : 2023-08-16

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    VAL-CIT-PAB-MMAE

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    VAL-CIT-PAB-MMAE

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40431

    Submission : 2024-08-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    WUXI ADHERENT HEK293T (WAHT)

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    WUXI ADHERENT HEK293T (WAHT)

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 32693

    Submission : 2019-01-02

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    LENTIVIRAL VECTOR

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    LENTIVIRAL VECTOR

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 33124

    Submission : 2018-12-28

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    MORPHOLINO GUANINE PHOSPHORAMIDOCHL...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    MORPHOLINO GUANINE PHOSPHORAMIDOCHL...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37861

    Submission : 2022-12-28

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    MORPHOLINO THYMINE PHOSPHORAMIDOCHL...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    MORPHOLINO THYMINE PHOSPHORAMIDOCHL...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37862

    Submission : 2022-12-28

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    Payload-linker Exatecan Mesylate

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    02

    Payload-linker Mc-mmaf

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    03

    “monomethyl Auristatin E (mmae)”

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    04

    2' -moe A(bz) Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2' -moe A(bz) Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40392

    Submission : 2024-09-30

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    2'-moe G(ibu) Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-moe G(ibu) Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40389

    Submission : 2024-09-30

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    2'-moe Mec(bz) Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-moe Mec(bz) Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40390

    Submission : 2024-09-30

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    2'-moe T Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-moe T Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40391

    Submission : 2024-09-30

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    2'-ome A(bz) Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-ome A(bz) Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40395

    Submission : 2024-10-10

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    2'-ome G(ibu) Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-ome G(ibu) Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40393

    Submission : 2024-10-10

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    2'-ome U Amidite

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    2'-ome U Amidite

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40396

    Submission : 2024-10-10

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    Inabogliflozin

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Inabogliflozin

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    Registrant Name : Daewoong Pharmaceutical Co., Ltd.

    Registration Date : 2022-11-30

    Registration Number : Su171-4-ND

    Manufacturer Name : Shanghai SynTheAll Pharmaceuti...

    Manufacturer Address : No. 9 Yuegong Rd., Jinshan Subbranch(West), Chemistry Industry Zone, Shanghai, 201507...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Inabogliflozin

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Inabogliflozin

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    Registrant Name : Easy Biopharm Co., Ltd.

    Registration Date : 2023-03-10

    Registration Number : Su171-4-ND(1)

    Manufacturer Name : Shanghai SynTheAll Pharmaceuti...

    Manufacturer Address : No. 9 Yuegong Rd., Jinshan Subbranch(West), Chemistry Industry Zone, Shanghai, 201507...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    03

    Roxadustat

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Roxadustat

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    Registrant Name : AstraZeneca Korea Ltd.

    Registration Date : 2021-07-09

    Registration Number : Su248-16-ND

    Manufacturer Name : Shanghai SyntheAll Pharmaceuti...

    Manufacturer Address : No.9, Yuegong Road, Jinshan District, Shanghai, 201507, China

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    04

    zanubrutinib

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    zanubrutinib

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    Registrant Name : Biwon Medison Korea Co., Ltd.

    Registration Date : 2022-09-16

    Registration Number : Su969-1-ND

    Manufacturer Name : Changzhou SynTheAll Pharmaceut...

    Manufacturer Address : 589 North Yulong Road, Xinbei District Changzhou, Jiangsu, 213127, China

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    NDC API

    read-more
    read-more

    01

    ELEXACAFTOR

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    ELEXACAFTOR

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-445

    Start Marketing Date : 2019-10-21

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    IVACAFTOR

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    IVACAFTOR

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-770

    Start Marketing Date : 2014-07-29

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    NIRAPARIB TOSYLATE MONOHYDRATE

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    NIRAPARIB TOSYLATE MONOHYDRATE

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-208

    Start Marketing Date : 2018-08-31

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    SPARSENTAN

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    SPARSENTAN

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-021

    Start Marketing Date : 2023-02-17

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    TELOTRISTAT ETIPRATE

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    TELOTRISTAT ETIPRATE

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-606

    Start Marketing Date : 2017-05-11

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    TEZACAFTOR

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    TEZACAFTOR

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-661

    Start Marketing Date : 2018-02-12

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    TIRZEPATIDE

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    TIRZEPATIDE

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-599

    Start Marketing Date : 2025-04-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR HUMAN PR...

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    ZANUBRUTINIB

    China
    BIO Partnering at JPM
    Not Confirmed
    arrow

    ZANUBRUTINIB

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi AppTec

    NDC Package Code : 24538-311

    Start Marketing Date : 2019-11-14

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Revium Rx Progresses to Phase 1 for Nano-Mupirocin Against Antibiotic-Resistant Infections

    Details:

    Nano-Mupirocin, an antibiotic targeting bacterial isoleucyl-tRNA synthetase, shows promise in treating Methicillin-Resistant Staphylococcus aureus (MRSA).


    Lead Product(s): Nano-Mupirocin,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: IND EnablingProduct Type: Antibiotic

    Recipient: Revium Rx

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 21, 2025

    blank

    01

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nano-Mupirocin,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Recipient : Revium Rx

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Revium Rx Progresses to Phase 1 for Nano-Mupirocin Against Antibiotic-Resistant Infections

    Details : Nano-Mupirocin, an antibiotic targeting bacterial isoleucyl-tRNA synthetase, shows promise in treating Methicillin-Resistant Staphylococcus aureus (MRSA).

    Product Name : Undisclosed

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    October 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide

    Details:

    Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.


    Lead Product(s): SPU-16,Inapplicable

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Peptide, Unconjugated

    Sponsor: Silo Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 07, 2024

    blank

    02

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPU-16,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Silo Pharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide

    Details : Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    August 07, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

    Details:

    Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.


    Lead Product(s): Resecabtagene Autoleucel,Inapplicable

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Cell & Gene Therapy

    Sponsor: Cabaletta Bio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 22, 2023

    blank

    03

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Resecabtagene Autoleucel,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Cabaletta Bio

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Inc...

    Details : Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies...

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Undisclosed

    August 22, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies

    Details:

    Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.


    Lead Product(s): INT2104,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Cell & Gene Therapy

    Sponsor: Interius BioTherapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership May 08, 2023

    blank

    04

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INT2104,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Interius BioTherapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapi...

    Details : Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Undisclosed

    May 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

    Details:

    PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility.


    Lead Product(s): PAS-004,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: IND EnablingProduct Type: Miscellaneous

    Recipient: Pasithea Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 18, 2023

    blank

    05

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : PAS-004,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Recipient : Pasithea Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-...

    Details : PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and m...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    January 18, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

    Details:

    Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.


    Lead Product(s): Undisclosed,Inapplicable

    Therapeutic Area: Technology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Undisclosed

    Sponsor: Johnson & Johnson Innovative Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 11, 2022

    blank

    06

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed,Inapplicable

    Therapeutic Area : Technology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

    Details : Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    August 11, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

    Details:

    TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.


    Lead Product(s): TFC-1326,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Miscellaneous

    Sponsor: Sirona Biochem Corp

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 22, 2022

    blank

    07

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TFC-1326,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Sirona Biochem Corp

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound...

    Details : TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    June 22, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies

    Details:

    The partnership initially focusses on Chimeric’s two autologous CAR T-cell therapies for solid tumours: CHM 2101, currently in late preclinical for gastrointestinal cancers and CHM 1101 (CLTX CAR T), currently in single-site phase 1 for recurrent or progressive glioblastoma.


    Lead Product(s): CHM 1101,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cell & Gene Therapy

    Recipient: Chimeric Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership April 12, 2022

    blank

    08

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CHM 1101,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Chimeric Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies

    Details : The partnership initially focusses on Chimeric’s two autologous CAR T-cell therapies for solid tumours: CHM 2101, currently in late preclinical for gastrointestinal cancers and CHM 1101 (CLTX CAR T), currently in single-site phase 1 for recurrent or pr...

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Undisclosed

    April 12, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies

    Details:

    Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.


    Lead Product(s): Undisclosed,Inapplicable

    Therapeutic Area: Technology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Undisclosed

    Sponsor: Orbit Discovery

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership March 07, 2022

    blank

    09

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi AppTec

    China
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed,Inapplicable

    Therapeutic Area : Technology

    Highest Development Status : Discovery Platform

    Partner/Sponsor/Collaborator : Orbit Discovery

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Techno...

    Details : Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    March 07, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    InnoCare Orelabrutinib Included in Priority Review by NMPA

    Details:

    The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).


    Lead Product(s): Orelabrutinib,Inapplicable

    Therapeutic Area: Neurology Brand Name: Hibruka

    Study Phase: Phase IIProduct Type: Miscellaneous

    Recipient: InnoCare Pharma

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 13, 2021

    blank

    10

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    WuXi Advanced Therapies

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Orelabrutinib,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Recipient : InnoCare Pharma

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    InnoCare Orelabrutinib Included in Priority Review by NMPA

    Details : The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic l...

    Product Name : Hibruka

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 13, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact WuXi AppTec and get a quotation

    WuXi AppTec is a supplier offers 27 products (APIs, Excipients or Intermediates).

    Find a price of Exatecan bulk with DMF offered by WuXi AppTec

    Find a price of Mafodotin [Usan] bulk with DMF offered by WuXi AppTec

    Find a price of Monomethyl Auristatin E bulk with DMF offered by WuXi AppTec

    Find a price of MC-VC-PAB-MMAE bulk with DMF offered by WuXi AppTec

    Find a price of PAYLOAD-LINKER VCMMAE bulk with DMF offered by WuXi AppTec

    Find a price of VAL-CIT-PAB-MMAE bulk with DMF offered by WuXi AppTec

    Find a price of 2'-OME A(BZ) AMIDITE bulk offered by WuXi AppTec

    Find a price of 2'-MOE T AMIDITE bulk offered by WuXi AppTec

    Find a price of CPG OLIGONUCLEOTIDE 1018 bulk offered by WuXi AppTec

    Find a price of LENTIVIRAL VECTOR bulk offered by WuXi AppTec

    Find a price of 2'-OME G(IBU) AMIDITE bulk offered by WuXi AppTec

    Find a price of 2'-MOE MEC(BZ) AMIDITE bulk offered by WuXi AppTec

    Find a price of MORPHOLINO THYMINE PHOSPHORAMIDOCHLORIDATE bulk offered by WuXi AppTec

    Find a price of WUXI ADHERENT HEK293T (WAHT) bulk offered by WuXi AppTec

    Find a price of 2'-OME U AMIDITE bulk offered by WuXi AppTec

    Find a price of 2' -MOE A(BZ) AMIDITE bulk offered by WuXi AppTec

    Find a price of 2'-MOE G(IBU) AMIDITE bulk offered by WuXi AppTec

    Find a price of MORPHOLINO GUANINE PHOSPHORAMIDOCHLORIDATE bulk offered by WuXi AppTec

    Find a price of CAS No 1613220-15-7 bulk offered by WuXi AppTec

    Find a price of Elexacaftor bulk offered by WuXi AppTec

    Find a price of Enavogliflozin bulk offered by WuXi AppTec

    Find a price of Ivacaftor bulk offered by WuXi AppTec

    Find a price of Roxadustat bulk offered by WuXi AppTec

    Find a price of Sparsentan bulk offered by WuXi AppTec

    Find a price of Telotristat Etiprate bulk offered by WuXi AppTec

    Find a price of Tezacaftor bulk offered by WuXi AppTec

    Find a price of Tirzepatide bulk offered by WuXi AppTec

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search